文献速递肝病

「健康志愿者」有多健康?生物医学研究志愿者池中非酒精性脂肪性肝病的患病率

How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.
PubMed 文献 · Hepatology · 2017-07-27

该横断面研究纳入2011至2015年间在149项临床试验中作为健康志愿者、无已知肝病的3160名受试者,推定非酒精性脂肪性肝病(pNF)占27.9%,仅14%的试验同时使用BMI和ALT筛查,pNF受试者研究期间3-4级ALT升高例数多于健康对照(4例对1例)。

要点

  • 健康志愿者中推定非酒精性脂肪性肝病常见,149项试验中仅14%同时用BMI和ALT筛查。
  • pNF受试者881例(27.9%),其甘油三酯、低密度脂蛋白胆固醇、HbA1c较高而高密度脂蛋白胆固醇较低(P < 0.001)。
  • 研究期间3-4级ALT升高少见,但pNF受试者多于健康对照(4例对1例)。

核心结论

  • 非酒精性脂肪性肝病在临床试验志愿者中常见且常被忽视,尽管其可能影响受试者安全和研究结果有效性。
  • 作者认为提高对非酒精性脂肪性肝病患病率的认识并采用更严格的ALT界值可能改善这一问题。

研究设计与样本

  • 横断面研究,纳入2011至2015年间被归类为健康志愿者且无已知肝病的受试者。
  • 共3160名受试者参与149项临床试验,每名受试者参与1至29项试验。
  • 受试者分为推定非酒精性脂肪性肝病(pNF)、健康非NAFLD对照和不确定三类。
  • pNF定义为女性丙氨酸氨基转移酶(ALT)≥ 20或男性ALT ≥ 31且体重指数(BMI)> 25 kg/m2。
  • 149项试验包括101项非干预性试验、33项干预性试验和15项疫苗试验。

主要发现

  • 1732名受试者(55%)BMI > 25 kg/m2,1382名(44%)ALT异常。
  • pNF存在于881名受试者(27.9%),这些受试者较健康对照年长,甘油三酯、低密度脂蛋白胆固醇和HbA1c较高、高密度脂蛋白胆固醇较低(P < 0.001)。
  • 招募NAFLD受试者作为对照对研究有效性的影响估计为可能、很可能和不太可能分别见于10、41和98项试验。
  • pNF受试者比例(28%-29%)不因影响估计不同而不同。
  • 仅14%的试验同时使用BMI和ALT进行筛查,ALT筛查界值基于本地参考值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Healthy volunteers are crucial for biomedical research. Inadvertent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can compromise study validity and subject safety. Given the rising prevalence of NAFLD in the general population, we sought to identify its prevalence and potential impact in volunteers for clinical trials. We conducted a cross-sectional study of subjects who were classified as healthy volunteers between 2011 and 2015 and had no known liver disease. Subjects were classified as presumed NAFLD (pNF; alanine aminotransferase [ALT] level ≥ 20 for women or ≥ 31 for men and body mass index [BMI] > 25 kg/m2 ), healthy non-NAFLD controls (normal ALT and BMI), or indeterminate. A total of 3160 subjects participated as healthy volunteers in 149 clinical trials (1-29 trials per subject); 1732 of these subjects (55%) had a BMI > 25 kg/m2 and 1382 (44%) had abnormal ALT. pNF was present in 881 subjects (27.9%), and these subjects were older than healthy control subjects and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower high-density lipoprotein cholesterol (P < 0.001 for all). The 149 trials included 101 non-interventional, 33 interventional, and 15 vaccine trials. The impact on study validity of recruiting NAFLD subjects as controls was estimated as likely, probable, and unlikely in 10, 41, and 98 trials, respectively. The proportion of pNF subjects (28%-29%) did not differ by impact. Only 14% of trials used both BMI and ALT for screening. ALT cutoffs for screening were based on local reference values. Grade 3-4 ALT elevations during the study period were rare but more common in pNF subjects than in healthy control subjects (4 versus 1). CONCLUSION: NAFLD is common and often overlooked in volunteers for clinical trials, despite its potential impact on subject safety and validity of study findings. Increased awareness of NAFLD prevalence and stricter ALT cutoffs may ameliorate this problem. (Hepatology 2017;66:825-833).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Takyar V, Nath A, Beri A, et al. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology. 2017. PMID: 28470683. doi:10.1002/hep.29247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。